Newsroom

Industry News

18 Sep

NAC Global Technologies Announces Successful Test of New Turbine Technology

NAC Global Technologies (OTCBB: NACG) today announced the successful first stage testing of its HGT Turbine Drive, a harmonic gearing transmission technology for fluid and wind turbine energy production. Mr. Vincent Genovese, Chairman and CEO of NAC, said, “We are very pleased to announce another milestone in NAC’s development...

Read more

18 Sep

Inovio to Present at Upcoming Investor Conferences

Inovio Pharmaceuticals, Inc. (INO) announced today CEO Dr. J. Joseph Kim will be presenting at two upcoming investor conferences in New York, NY: Biocentury’s NewsMakers in the Biotech Industry Conference and Bernstein’s Genes as Drugs Event. NewsMakers in the Biotech Industry September 26, 2014 2:30 PM ET Investor Presentation...

Read more

18 Sep

Capricor Presents Safety and Preliminary Efficacy Results From ALLSTAR Phase I Clinical Trial at TCT 2014

Capricor Therapeutics, Inc. (CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of cardiovascular diseases, presented an abstract entitled “ALLogeneic Heart STem Cells ToAchieve Myocardial Regeneration (ALLSTAR): The Six Month Phase I Safety Results” with an oral presentation by Dr. Raj R. Makker, M.D., of Cedars-Sinai...

Read more

17 Sep

Hydrocarb Energy Announces Significant Increases in Oil and Gas Reserves

– Company’s PV-10 value doubled and proved reserves increased more than 50% for the year ended 2014 — Recent infrastructure improvements to further increase oil and gas production  Hydrocarb Energy Corporation (HECC) recently reported substantial increases to its PV-10 oil and gas reserves. The company also recently commenced operations to...

Read more

17 Sep

Nxt-ID, Inc. Announces Closing of Public Offering of Common Stock and Warrants

Nxt-ID, Inc. (Nasdaq:NXTD and NXTDW) (“Nxt-ID” or the “Company”) announced today that it has closed the previously announced underwritten public offering of its common stock and warrants. The Company offered 2,127,273 shares of common stock and 2,127,273 warrants to purchase shares of common stock, at a combined price to the...

Read more

16 Sep

Boston Therapeutics to Present Findings of BTI-320 as Therapy for Glycemic Control at 50th Annual Meeting of European Association for the Study of Diabetes

Boston Therapeutics, Inc. (OTCQB: BTHE) (“Boston Therapeutics” or “the Company”), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, will present data on BTI-320, its lead drug candidate, as a poster presentation at the 50th Annual Meeting of the European Association for the Study of Diabetes...

Read more

16 Sep

Actinium to Present at the 21st Annual BioCentury NewsMakers Conference on Friday, September 26th

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Dr. Kaushik J. Dave, President and CEO of Actinium will present at the 21st Annual BioCentury NewsMakers Conference on Friday, September 26,...

Read more

Page 1 of 1712345...10...Last »

Latest Tweets